cancer immunotherapy 

Statements about this table:
in 2011 , the approved treatment for hodgkin lymphoma and anaplastic large - cell lymphoma be adcetris
the target for non - hodgkin lymphoma be cd20
the approval date for panitumumab be 2006 and target epidermal growth factor receptor
there be 1 target with an anibody that have an approval date of 1997
approve treatment for the antibody bevacizumab be colorectal cancer
the approved treatment target for non - hodgkin lymphoma be cd20
epidermal growth factor receptor have approval date of 2004 and 2006
1 of the antibody be approve in 1997
the approved treatment with approval date 2004 for the target cd30 be hodgkin lymphoma and anaplastic large - cell lymphoma
hodgkin lymphoma and anaplastic large - cell lymphoma use cetuximab to target cd30
the brand name for the antibody brentuximab vedotin be campath
when the approve treatment be non - hodgkin lymphoma , the target be cd33
the target with an approval date of 1997 be epidermal growth factor receptor
the brand name for the antibody brentuximab vedotin be vectibix
antibody
brand name
approval date
type
target
approved treatment (s)
alemtuzumab
campath
2001
humanized
cd52
chronic lymphocytic leukemia
bevacizumab
avastin
2004
humanized
vascular endothelial growth factor
colorectal cancer
brentuximab vedotin
adcetris
2011
chimeric
cd30
hodgkin lymphoma , anaplastic large - cell lymphoma
cetuximab
erbitux
2004
chimeric
epidermal growth factor receptor
colorectal cancer
antibody
brand name
approval date
type
target
approved treatment (s)
gemtuzumab ozogamicin
mylotarg
2000
humanized
cd33
acute myelogenous leukemia (with calicheamicin )
panitumumab
vectibix
2006
human
epidermal growth factor receptor
colorectal cancer
rituximab
rituxan , mabthera
1997
chimeric
cd20
non - hodgkin lymphoma